Government-Owned Inventions; Availability for Licensing, 16376-16377 [2018-07822]
Download as PDF
<![CDATA[
16376
Federal Register / Vol. 83, No. 73 / Monday, April 16, 2018 / Notices
request a leave of absence the first
academic year.
The following reports must be sent to
the IHSSP at the identified time frame.
Each scholarship awardee will have
access to online Student and Service
Commitment Handbooks and required
program forms and instructions on
when, how, and to whom these must be
submitted, by logging into the IHSSP
website at www.ihs.gov/scholarship. If a
scholarship awardee fails to submit
these forms and reports as required,
they will be ineligible for continuation
of scholarship support and scholarship
award payments will be discontinued.
A. Recipient’s and Initial Progress
Report
Within thirty (30) days from the
beginning of each semester/trimester/
quarter, scholarship awardees must
submit a Recipient’s Initial Program
Progress Report (Form IHS–856–8,
found on the IHS Scholarship Program
website at: https://www.ihs.gov/
scholarship/programresources/
studentforms/).
B. Transcripts
Within thirty (30) days from the end
of each academic period, i.e., semester/
trimester/quarter, or summer session,
scholarship awardees must submit an
Official Transcript showing the results
of the classes taken during that period.
C. Notification of Academic Problem
If at any time during the semester/
trimester/quarter, scholarship awardees
are advised to reduce the number of
credit hours for which they are enrolled
below the minimum of the 12 (or the
number of hours considered by their
school as full-time) for a full-time
student or at least 6 hours for part-time
students, or if they experience academic
problems, they must submit this report
(Form IHS–856–9, found on the IHS
Scholarship Program website at:
www.ihs.gov/scholarship/
programresources/studentforms/).
D. Change of Status
srobinson on DSK3G9T082PROD with NOTICES
• Change of Academic Status
Scholarship awardees must
immediately notify their Scholarship
Program Analyst if they are placed on
academic probation, dismissed from
school, or voluntarily withdraw for any
reason (personal or medical).
• Change of Health Discipline
Scholarship awardees may not change
from the approved IHSSP health
discipline during the school year. If an
unapproved change is made,
scholarship payments will be
discontinued.
VerDate Sep<11>2014
19:42 Apr 13, 2018
Jkt 244001
• Change in Graduation Date
Any time that a change occurs in a
scholarship awardee’s expected
graduation date, they must notify their
Scholarship Program Analyst
immediately in writing. Justification
must be attached from the school
advisor. Approvals must be made by the
Branch Chief of Scholarships.
VII. Agency Contacts
VIII. Other Information
The Public Health Service (PHS) is
committed to achieving the health
promotion and disease prevention
objectives of Healthy People 2020, a
PHS-led activity for setting priority
areas. This program announcement is
related to the priority area of Education
and Community-Based Programs.
Potential applicants may download a
copy of Healthy People 2020 from
https://www.healthypeople.gov.
Interested individuals are reminded
that the list of eligible IHSSP health and
allied professions is effective for
applicants for the 2018–2019 academic
year. These priorities will remain in
effect until superseded. Applicants who
apply for health career categories not
listed as a priorities during the current
scholarship cycle will not be considered
for a scholarship award.
Dated: April 5, 2018.
Michael Weahkee,
Assistant Surgeon General, U.S. Public Health
Service, Acting Director, Indian Health
Service.
[FR Doc. 2018–07797 Filed 4–13–18; 8:45 am]
BILLING CODE 4165–16–P
Frm 00092
Fmt 4703
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Amy Petrik., Ph.D., 240–627–3721;
amy.petrik@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
1. Questions on the application
process may be directed to the
appropriate IHS Area Scholarship
Coordinator.
2. Questions on other programmatic
matters may be addressed to: Ms. Reta
Brewer, Chief, Scholarship Program,
5600 Fishers Lane, Mail Stop: OHR
(11E53A), Rockville, Maryland 20857,
Telephone: (301) 443–6197 (This is not
a toll-free number).
3. Questions on payment information
may be directed to: Mr. Craig Boswell,
Grants Scholarship Coordinator,
Division of Grants Management, Indian
Health Service, 5600 Fishers Lane, Mail
Stop: (09E65A), Rockville, Maryland
20857, Telephone: (301) 443–0056 (This
is not a toll-free number).
PO 00000
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Sfmt 4703
Prefusion Coronavirus Spike Proteins
and Their Use
Description of Technology
Coronaviruses (CoVs) can cause
severe respiratory disease with high
fatality rates in humans. The 2002–2003
SARS-CoV epidemic resulted in 8098
cases and 744 deaths, and MERS-CoV,
which emerged in 2012, has resulted in
2144 cases and over 750 deaths as of
March 2018. Currently, there are no
effective prophylactic or therapeutic
measures, and because other CoVs are
poised to emerge as new human
pathogens, there is a need to define a
general CoV vaccine solution. Past
efforts to develop CoV vaccines have
used whole-inactivated virus, liveattenuated virus, recombinant protein
subunit, or genetic approaches.
CoV spike (S) proteins mediate
cellular attachment and membrane
fusion and are therefore the target of
protective antibodies. Inventors at the
Vaccine Research Center of the National
Institute of Allergy and Infectious
Diseases have developed a novel CoV S
protein vaccine antigen. This
E:\FR\FM\16APN1.SGM
16APN1
srobinson on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 83, No. 73 / Monday, April 16, 2018 / Notices
technology employs protein engineering
to stabilize S in its prefusion
conformation, preventing structural
rearrangement, and exposing
antigenically preferable surfaces. The
technology has been applied to several
CoV spikes, including those from
human-relevant viruses, such as HKU1CoV, SARS-CoV, and MERS-CoV.
Particularly for MERS–COV, stabilized S
proteins have been shown to elicit
superior neutralizing antibody
responses up to 10-fold higher in animal
models and protect mice against lethal
MERS-CoV infection. This technology is
applicable for delivery via other
platforms, such as mRNA.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
The stabilized prefusion coronavirus
spike protein can be used as a vaccine
antigen to elicit robust neutralizing
antibody responses.
Competitive Advantages:
• Improved immunogenicity
compared to other coronavirus S
vaccine formulations.
• Increased protein expression,
stability, and manufacturability
compared to wild-type CoV S.
Development Stage:
• In vivo data available (animal).
Inventors: Barney Graham (NIAID),
Masaru Kanekiyo (NIAID), M. Gordon
Joyce (NIAID), Kizzmekia Corbett
(NIAID), Hadi Yassine (NIAID), Andrew
Ward (Scripps), Robert Kirchdoefer
(Scripps), Christopher Cottrell (Scripps),
Jesper Pallesen (Scripps), Hannah
Turner (Scripps), Nianshuang Wang
(Dartmouth), Jason McLellan
(Dartmouth),
Intellectual Property: HHS Reference
No. E–234–2016/0, U.S. Provisional
Patent Application Number 62/412,703,
filed October 25, 2016, PCT Patent
Application PCT/US2017/058370 filed
October 25, 2017.
Licensing Contact: Amy Petrik, Ph.D.,
240–627–3721; amy.petrik@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize norovirus diagnostics or
vaccines. For collaboration
opportunities, please contact Amy
Petrik, Ph.D., 240–627–3721;
amy.petrik@nih.gov.
VerDate Sep<11>2014
19:42 Apr 13, 2018
Jkt 244001
16377
Dated: April 10, 2018.
Michelle D. Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: April 5, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2018–07820 Filed 4–13–18; 8:45 am]
[FR Doc. 2018–07822 Filed 4–13–18; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Sleep Disorders Research
Advisory Board.
This meeting is open to the public but
is being held by virtual/teleconference.
No physical meeting location is
provided for any interested individuals
to listen to and/or participate in the
meeting. Any individual interested in
listening to the meeting discussions
must: access the website https://
nih.webex.com/nih/onstage/
g.php?MTID=e9a4cbcaac003afd915c2c
94a8c787585 and enter Event Password:
sdrab or call-in toll number 1–650–479–
3208 and enter access code: 625 446
354, for access to the meeting.
Individuals require special assistance,
should notify the Contact Person listed
below in advance of the meeting.
Name of Committee: Sleep Disorders
Research Advisory Board.
Date: April 27, 2018.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: Discussion of NIH Sleep Disorders
Research Plan Revision.
Place: National Institutes of Health, Two
Rockledge Center, Conference Room 10167,
6701 Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Michael J. Twery, Ph.D.,
Director, National Center on Sleep Disorders
Research Division of Lung Diseases, National
Heart, Lung, and Blood Institute, National
Institutes of Health, 6701 Rockledge Drive,
Suite 10042, Bethesda, MD 20892–7952, 301–
435–0199, twerym@nhlbi.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations of receiving input from committee
members prior to presenting the plan to other
audiences for comment and meeting a
legislative reporting deadline.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Amy Petrik, 240–627–3721;
amy.petrik@nih.gov. Licensing
information and copies of the U.S.
patent application listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
Novel Multivalent Nanoparticle
Vaccines
Description of Technology: Current
seasonal influenza vaccines are
designed to elicit immunity to
circulating strains of influenza each
year. The targeted strains are selected
based on predictions of which strains
are likely to be predominant in the
human population for a given year. This
prediction must be made well ahead of
the influenza season to allow time for
vaccine production and can be
inaccurate.
Scientists at NIAID’s Vaccine
Research Center are developing an
alternative approach for design and
production of seasonal influenza
vaccines. The design includes
recombinant fusion proteins that self-
E:\FR\FM\16APN1.SGM
16APN1
]]>Agencies
[Federal Register Volume 83, Number 73 (Monday, April 16, 2018)]
[Notices]
[Pages 16376-16377]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-07822]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Amy Petrik., Ph.D., 240-627-3721;
[email protected]. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Prefusion Coronavirus Spike Proteins and Their Use
Description of Technology
Coronaviruses (CoVs) can cause severe respiratory disease with high
fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in
8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has
resulted in 2144 cases and over 750 deaths as of March 2018. Currently,
there are no effective prophylactic or therapeutic measures, and
because other CoVs are poised to emerge as new human pathogens, there
is a need to define a general CoV vaccine solution. Past efforts to
develop CoV vaccines have used whole-inactivated virus, live-attenuated
virus, recombinant protein subunit, or genetic approaches.
CoV spike (S) proteins mediate cellular attachment and membrane
fusion and are therefore the target of protective antibodies. Inventors
at the Vaccine Research Center of the National Institute of Allergy and
Infectious Diseases have developed a novel CoV S protein vaccine
antigen. This
[[Page 16377]]
technology employs protein engineering to stabilize S in its prefusion
conformation, preventing structural rearrangement, and exposing
antigenically preferable surfaces. The technology has been applied to
several CoV spikes, including those from human-relevant viruses, such
as HKU1-CoV, SARS-CoV, and MERS-CoV. Particularly for MERS-COV,
stabilized S proteins have been shown to elicit superior neutralizing
antibody responses up to 10-fold higher in animal models and protect
mice against lethal MERS-CoV infection. This technology is applicable
for delivery via other platforms, such as mRNA.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications: The stabilized prefusion
coronavirus spike protein can be used as a vaccine antigen to elicit
robust neutralizing antibody responses.
Competitive Advantages:
Improved immunogenicity compared to other coronavirus S
vaccine formulations.
Increased protein expression, stability, and
manufacturability compared to wild-type CoV S.
Development Stage:
In vivo data available (animal).
Inventors: Barney Graham (NIAID), Masaru Kanekiyo (NIAID), M.
Gordon Joyce (NIAID), Kizzmekia Corbett (NIAID), Hadi Yassine (NIAID),
Andrew Ward (Scripps), Robert Kirchdoefer (Scripps), Christopher
Cottrell (Scripps), Jesper Pallesen (Scripps), Hannah Turner (Scripps),
Nianshuang Wang (Dartmouth), Jason McLellan (Dartmouth),
Intellectual Property: HHS Reference No. E-234-2016/0, U.S.
Provisional Patent Application Number 62/412,703, filed October 25,
2016, PCT Patent Application PCT/US2017/058370 filed October 25, 2017.
Licensing Contact: Amy Petrik, Ph.D., 240-627-3721;
[email protected].
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize norovirus diagnostics or vaccines.
For collaboration opportunities, please contact Amy Petrik, Ph.D., 240-
627-3721; [email protected].
Dated: April 5, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-07822 Filed 4-13-18; 8:45 am]
BILLING CODE 4140-01-P
